Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA (N2) NSCLC
Xiaoliang Zhao1,2,3, Xiaohua Wen4, Wei Wei1,2,3
1Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Background:
Endostar (rh-endostatin) is a new recombinant human endostatin, which could inhibit cell proliferation, angiogenesis, and tumor growth.
Objective:
To explore anti-angiogenesis short-term efficacy combined with neoadjuvant chemotherapy for stage IIIA (N2) non-small cell lung cancer (NSCLC), and identify the potential predictive factors.
Methods:
We pathologically examined 26 patients diagnosed with stage IIIA (N2) NSCLC who received NP chemotherapy alone or combined with Endostar, respectively.
Results:
Our results indicated that total clinical benefit rate (CBR) 87.5% and 64% (p= 0.76), respectively. The clinical benefit (CB) patients in the treatment group showed significant changes in endothelial progenitor cells (EPC), vascular endothelial growth factor (VEGF), blood flow (BF), permeability surface (PMS), and microvascular density (MVD) before and after treatment. Compared with CB patients in the control group, changes in EPC and MVD (only) before and after treatment were significant. The variation of EPC, PMS, and MVD before and after treatment in the treatment group showed positive correlation with tumor regression rate (TRR) and the variation of MVD, whereas those of EPC and PMS demonstrated positive correlations with variation of MVD before and after treatment.
Conclusion:
Our findings suggested that PMS and EPC may be used as a predictive factor for the short-term efficacy of the combined therapy in NSCLC.
Insights
Endostar combined with chemotherapy shows potential for treating non-small cell lung cancer (NSCLC). Permeability surface (PMS) and endothelial progenitor cells (EPC) may predict treatment effectiveness.
Area of Science:
- Oncology
- Cancer Research
- Angiogenesis Inhibition
Background:
- Endostar (rh-endostatin) is a novel recombinant human endostatin.
- Endostar inhibits tumor cell proliferation, angiogenesis, and growth.
Purpose of the Study:
- To evaluate the anti-angiogenesis efficacy of Endostar combined with neoadjuvant chemotherapy.
- To identify predictive factors for stage IIIA (N2) non-small cell lung cancer (NSCLC) treatment.
Main Methods:
- Pathological examination of 26 stage IIIA (N2) NSCLC patients.
- Comparison of NP chemotherapy alone versus NP chemotherapy with Endostar.
Main Results:
- The combination therapy group showed significant changes in endothelial progenitor cells (EPC), vascular endothelial growth factor (VEGF), blood flow (BF), permeability surface (PMS), and microvascular density (MVD).
- Changes in EPC and MVD were significant compared to the control group.
- Variations in EPC, PMS, and MVD correlated with tumor regression rate (TRR) and MVD changes.
Conclusions:
- Permeability surface (PMS) and endothelial progenitor cells (EPC) may serve as predictive factors for short-term efficacy.
- The combined Endostar and chemotherapy approach shows promise for NSCLC treatment.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019